---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-004000"
form_type: "8-K"
ticker: "FOXO"
cik: "0001812360"
company_name: "FOXO TECHNOLOGIES INC."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:25:45.104521+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FOXO CEO reports change of control, debt restructuring, and plans for revenue growth

## Summary
- Shareholders meeting Jan 17, 2025 concluded 2024 acquisition agreements, resulting in change of control of company.
- Restructured over $21M in shareholders' equity, turning deficit to meet NYSE continued listing requirements of >$4M equity.
- Acquired businesses have potential to deliver >$20M profitable net revenues per annum; focus on rural hospital and behavioral health.
- Converted approx $6M additional debt to equity via convertible preferred stock (not freely tradable).
- Plan to monetize epigenetics division (FOXO Labs) and pursue additional acquisitions in healthcare, including senior living.

## SEC filing metadata
- accession: 0001493152-25-004000
- form_type: 8-K
- ticker: FOXO
- cik: 0001812360
- company_name: FOXO TECHNOLOGIES INC.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812360/000149315225004000/0001493152-25-004000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812360/000149315225004000/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-004000
- JSON: https://secwatch.observer/filing/0001493152-25-004000.json
- Plain text: https://secwatch.observer/filing/0001493152-25-004000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.